Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation

NCT03244384 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT03244384
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03244384 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 3
Overall status
Active, not recruiting
Start date
November 3, 2017
Completion date
October 31, 2026
Enrollment
739 (estimated)
Sites
914

Conditions

As the registry lists them; a condition with its own page is linked.

localized renal pelvis and ureter urothelial carcinoma, locally advanced bladder urothelial carcinoma, locally advanced renal pelvis and ureter urothelial carcinoma, locally advanced ureter urothelial carcinoma, locally advanced urothelial carcinoma, stage ii bladder urothelial carcinoma ajcc v6 and v7, stage ii renal pelvis and ureter cancer ajcc v7, stage ii ureter cancer ajcc v7, stage iii bladder urothelial carcinoma ajcc v6 and v7, stage iii renal pelvis and ureter cancer ajcc v7, stage iii ureter cancer ajcc v7